STX1A (1-265) Human

Syntaxin-1A (1-265 a.a) Human Recombinant
Shipped with Ice Packs
In Stock

Description

Production and Biochemical Properties

STX1A (1-265) is typically expressed in E. coli due to its prokaryotic expression efficiency and cost-effectiveness. Key features include:

  • Molecular Weight: ~30.7 kDa (265 amino acids) .

  • Purity: >95% as determined by SDS-PAGE .

  • Formulation: PBS (pH 7.4), 10% glycerol, 1 mM DTT for stability .

Expression Systems Comparison

Host SystemPurityPost-Translational ModificationsApplications
E. coli>95%NoneStructural studies, antibody production
Tobacco plants>80%Glycosylation (partial)Native-like conformation studies
HEK-293 cells>80%Full glycosylation, phosphorylationFunctional assays (e.g., exocytosis)

Data from commercial sources highlight E. coli as the primary choice for high-yield production .

Functional Roles in Neurotransmission

STX1A (1-265) Human is pivotal in:

  • SNARE Complex Assembly: Forms a 4-helix bundle with SNAP-25 and VAMP2, driving synaptic vesicle fusion .

  • Calcium-Dependent Exocytosis: Binds synaptotagmin to regulate neurotransmitter release timing .

  • Pain Sensitivity: Overexpression in TRPV1+ nociceptive neurons causes pain insensitivity in 7q11.23 duplication syndrome (Dup7) .

Key Research Findings

Study FocusOutcomeSource
Nociceptive neuron functionSTX1A overexpression inhibits CGRP release via TRPV1+ DRG neurons
Synaptic plasticitySTX1A GSG265 mutation increases spontaneous neurotransmitter release
Williams syndrome intelligenceSTX1A transcript levels correlate with cognitive scores (r = 0.40)
Botulinum toxin C substrateCleaves STX1A to block exocytosis, disrupting neurotransmitter release

Clinical and Pathological Relevance

  • Pain Insensitivity: Dup7 patients with STX1A triplication exhibit reduced nociceptive signaling due to impaired TRPV1-mediated exocytosis .

  • Neurodegenerative Diseases: Altered STX1A levels in Alzheimer’s disease (AD) brains suggest synaptic dysfunction .

  • Intelligence Correlation: In Williams syndrome, STX1A expression levels predict 15.6% of cognitive variance .

Methodological Applications

STX1A (1-265) is used in:

  • Immunoblotting: Detects STX1A isoforms in neuronal lysates .

  • Cell Culture: Overexpression studies in DRG neurons to model pain pathophysiology .

  • Protein-Protein Interaction Assays: Binding studies with SNAP-25 or NSF .

Product Specs

Introduction
Syntaxin is a Q-SNARE protein found in the membrane that plays a crucial role in exocytosis. It comprises three main domains: an N-terminal regulatory domain (Habc), a SNARE domain (H3), and a single C-terminal transmembrane domain. The SNARE domain interacts with synaptobrevin and SNAP-25 to form the core SNARE complex, which is essential for vesicle fusion. During calcium-regulated exocytosis, synaptic vesicles release neurotransmitters. Syntaxins contribute to this process by ensuring the localization of synaptic vesicles and calcium channels to the presynaptic active zone, thereby enabling specific neurotransmitter release. Furthermore, syntaxins act as a substrate for botulinum neurotoxin type C, a metalloprotease known to inhibit exocytosis. This neurotoxin exhibits a strong affinity for a molecular complex that includes the alpha-latrotoxin receptor, which is involved in exocytosis.
Description
Recombinant Human STX1A, expressed in E. coli, is a single, non-glycosylated polypeptide chain consisting of 265 amino acids (1-265 a.a.). It has a molecular weight of 30.7 kDa. The protein has been purified using proprietary chromatographic techniques.
Physical Appearance
A clear, colorless solution that has been sterilized by filtration.
Formulation
The STX1A protein solution (1 mg/ml) is supplied in a buffer containing phosphate buffered saline (pH 7.4), 10% glycerol, and 1 mM DTT.
Stability
For short-term storage (2-4 weeks), the product can be stored at 4°C. For extended storage, it is recommended to freeze the product at -20°C. To ensure stability during long-term storage, consider adding a carrier protein (0.1% HSA or BSA). It is important to avoid repeated freeze-thaw cycles to maintain protein integrity.
Purity
The purity of the protein is greater than 95.0% as determined by SDS-PAGE analysis.
Synonyms
Syntaxin 1A, Neuron-Specific Antigen HPC-1, Syntaxin 1A (Brain), STX1, Syntaxin-1A, HPC-1, P35-1, SYN1A.
Source
Escherichia Coli.
Amino Acid Sequence
MKDRTQELRT AKDSDDDDDV AVTVDRDRFM DEFFEQVEEI RGFIDKIAEN VEEVKRKHSA ILASPNPDEK TKEELEELMS DIKKTANKVR SKLKSIEQSI EQEEGLNRSS ADLRIRKTQH STLSRKFVEV MSEYNATQSD YRERCKGRIQ RQLEITGRTT TSEELEDMLE SGNPAIFASG IIMDSSISKQ ALSEIETRHS EIIKLENSIR ELHDMFMDMA MLVESQGEMI DRIEYNVEHA VDYVERAVSD TKKAVKYQSK ARRKK.

Q&A

What are the key functional domains of STX1A and their significance in research models?

STX1A contains several key domains that are critical to its function:

  • SNARE domain: Essential for forming the SNARE complex with SNAP-25 and VAMP, driving membrane fusion

  • Juxtamembrane domain (JMD): Connects the SNARE domain to the transmembrane region

  • Transmembrane domain (TMD): Anchors the protein in the plasma membrane

  • N-terminal Habc domain: Regulates protein conformation and interactions with regulatory proteins like Munc18-1

Research has shown that the spatial relationship between these domains is critical for proper function. For example, mutations that disrupt the coupling between the SNARE domain and TMD or between JMD and TMD lead to significant alterations in neurotransmission .

What expression systems are most effective for producing functional STX1A (1-265) for research?

Multiple expression systems have been validated for producing STX1A (1-265), each with distinct advantages:

Expression HostPurity AchievedApplicationsAdvantages
E. coli>95%SDS-PAGE, WB, ELISAHigh yield, cost-effective
Yeast>90%ELISAProduces protein very close to the natural form
HEK-293 Cells>90%SDS, WBMammalian post-translational modifications
Wheat germNot specifiedWB, ELISA, AP, AAAlternative for difficult proteins

For functional studies of neurotransmission, proteins expressed in E. coli and purified to >95% purity have been successfully utilized in multiple studies .

What are the optimal conditions for assessing STX1A function in vesicle fusion assays?

To effectively study STX1A function in vesicle fusion:

  • Use lentiviral expression systems in STX1-null neurons to eliminate background effects from endogenous protein

  • Compare wild-type STX1A with mutant variants (particularly mutations in the JMD or coupling between domains)

  • Measure electrophysiological parameters including:

    • Excitatory postsynaptic current (EPSC) amplitude

    • EPSC charge analysis

    • Vesicular release probability (Pvr)

    • Frequency of miniature EPSCs (mEPSCs)

  • Maintain physiological calcium concentrations (1-2 mM) during experiments

These methodologies have revealed that even minor alterations in STX1A structure, such as the insertion of three amino acids (GSG) at specific positions, can dramatically alter neurotransmission properties .

How does STX1A (1-265) contribute to regulated vesicle fusion in neurons?

STX1A is a critical component of the SNARE complex, which provides the mechanical force necessary for synaptic vesicle fusion with the plasma membrane. Recent research has revealed several key mechanisms:

  • The force transfer from SNARE complex formation to membrane fusion is strictly regulated by the length and positioning of the JMD of STX1A

  • Even small alterations in this region (e.g., insertion of one extra helical turn) can abolish EPSC amplitude

  • Different regions of STX1A have distinct roles in regulating different aspects of neurotransmission

Specifically, experiments with STX1A GSG259 (insertion in the SNARE domain-TMD coupling region) and STX1A GSG265 (insertion in the JMD-TMD coupling region) demonstrated that these mutations reduced EPSC amplitude to almost zero, while having differential effects on EPSC charge (reduced by ~61% and ~40% respectively) .

What mechanisms explain STX1A's differential regulation of spontaneous versus evoked neurotransmitter release?

STX1A regulates spontaneous release through two distinct mechanisms:

  • Regulation through the C-terminal half of its SNARE domain

  • Regulation through the juxtamembrane domain (JMD) and transmembrane domain (TMD)

Experimental evidence shows that uncoupling of the SNARE domain and TMD (STX1A GSG259) had no significant effect on spontaneous neurotransmission, while uncoupling of the JMD and TMD (STX1A GSG265) increased miniature EPSC frequency approximately threefold compared to wild-type STX1A .

This differential regulation suggests that STX1A may serve as a molecular switch between different modes of neurotransmitter release, with distinct structural regions mediating different aspects of vesicle fusion.

What evidence links STX1A expression to autism spectrum disorders?

Several lines of evidence suggest a role for STX1A in autism spectrum disorders, particularly high-functioning autism (HFA):

  • Genetic evidence: Transmission disequilibrium tests identified associations between specific STX1A SNPs and HFA:

SNP IDp-valueAssociation with HFA
rs22934850.034Nominal association
rs47178060.033Nominal association
  • Expression analysis: STX1A mRNA expression in lymphocytes of drug-naive HFA patients was significantly higher (p=0.001) than in age- and sex-matched controls

  • Developmental correlation: SNPs showing associations were specifically related to early developmental abnormalities (ADI-R_D scores), suggesting STX1A might influence early neurodevelopmental processes .

How might aberrant STX1A function impact serotonergic neurotransmission in autism?

The link between STX1A and serotonergic function provides insight into its potential role in autism:

  • STX1A is known to regulate the serotonin transporter (5-HTT), a major therapeutic target in autism

  • Humans normally undergo a period of high brain serotonin synthesis capacity during early childhood, which is disrupted in autistic children

  • STX1A might influence this serotonergic system during critical developmental periods

Research suggests that abnormal STX1A expression may contribute to autism pathophysiology by disrupting serotonergic neurotransmission during critical developmental windows. This is supported by the observation that SNPs associated with HFA correlate with early developmental abnormalities rather than specific symptoms, suggesting a role in general pathophysiology rather than specific symptom manifestation .

What methodologies are most effective for studying STX1A-Munc18-1 interactions?

The interaction between STX1A and Munc18-1 is crucial for proper synaptic vesicle fusion. To effectively study this interaction:

  • Use purified recombinant proteins with various tags (His, GST) expressed in prokaryotic or eukaryotic systems

  • Employ protein-protein interaction assays:

    • Pull-down assays with immobilized tagged proteins

    • Surface plasmon resonance for real-time interaction kinetics

    • Isothermal titration calorimetry for thermodynamic parameters

  • For functional studies in neuronal contexts:

    • Generate domain deletion mutants (e.g., ΔHabc) to assess functional consequences

    • Utilize lentiviral expression in STX1-null neurons for electrophysiological assessment

    • Implement FRET-based approaches to visualize interactions in living cells

These techniques have revealed that STX1A and Munc18-1 are interdependent components of the synaptic vesicular release machinery, and their interaction is essential for proper neurotransmission .

How can researchers effectively design STX1A mutants to elucidate domain-specific functions?

Strategic design of STX1A mutants has proven valuable for understanding domain-specific functions:

This systematic approach has revealed that even subtle modifications (e.g., insertion of one extra helical turn into the JMD) can lead to position-specific physiological phenotypes, demonstrating the precise spatial requirements for STX1A function in neurotransmission .

Product Science Overview

Structure and Expression

The human recombinant Syntaxin-1A (1-265 a.a) is a full-length protein comprising 265 amino acids. It is expressed in Escherichia coli and has a purity greater than 95%, making it suitable for various biochemical applications such as SDS-PAGE . The protein is also known by several alternative names, including Neuron-specific antigen HPC-1, STX1A, and STX1 .

Function and Mechanism

Syntaxin-1A is primarily found in the brain and is essential for synaptic vesicle exocytosis. It interacts with other SNARE proteins, such as SNAP-25 and VAMP (vesicle-associated membrane protein), to form a SNARE complex. This complex brings the vesicle and plasma membranes close together, facilitating their fusion and the subsequent release of neurotransmitters .

The protein’s structure includes a transmembrane domain that anchors it to the plasma membrane and a cytoplasmic domain that interacts with other SNARE proteins. The interaction between Syntaxin-1A and its partners is highly regulated and crucial for the precise timing of neurotransmitter release, which is essential for proper neuronal communication .

Applications and Research

Recombinant Syntaxin-1A (1-265 a.a) is widely used in research to study the mechanisms of synaptic transmission and the role of SNARE proteins in vesicle fusion. It is also used in various assays to investigate the interactions between SNARE proteins and other regulatory factors involved in neurotransmitter release .

Understanding the function and regulation of Syntaxin-1A is important for elucidating the molecular basis of synaptic transmission and for developing potential therapeutic strategies for neurological disorders that involve synaptic dysfunction.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.